Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week Low - What's Next?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $36.71 and last traded at $37.08, with a volume of 184337 shares trading hands. The stock had previously closed at $38.69.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RARE shares. Wedbush reiterated a "neutral" rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. JPMorgan Chase & Co. lifted their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday. HC Wainwright reissued a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Piper Sandler reduced their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. Finally, Canaccord Genuity Group upped their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average target price of $92.79.

Remove Ads

Ultragenyx Pharmaceutical Stock Performance

The stock has a market capitalization of $3.50 billion, a price-to-earnings ratio of -5.97 and a beta of 0.67. The firm's fifty day simple moving average is $41.64 and its 200 day simple moving average is $46.84.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, insider John Richard Pinion sold 14,439 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the sale, the insider now owns 107,766 shares of the company's stock, valued at $4,536,948.60. The trade was a 11.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Theodore Alan Huizenga sold 967 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares of the company's stock, valued at $2,116,156.50. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 136,370 shares of company stock valued at $5,751,499 over the last three months. Company insiders own 5.80% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 493 shares during the last quarter. True Wealth Design LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter worth $43,000. Aster Capital Management DIFC Ltd bought a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth $35,000. Human Investing LLC acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at $42,000. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at about $83,000. Institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.